2025. Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 2 Trial. SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s692. DOI:https://doi.org/10.25251/w6str133.